Aquestive Therapeutics (NASDAQ:AQST) Posts Earnings Results, Misses Estimates By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST) announced its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01), FiscalAI reports. The company had revenue of $7.56 million for the quarter, compared to analysts’ expectations of $11.02 million.

Aquestive Therapeutics Price Performance

Shares of AQST traded down $0.06 during midday trading on Thursday, reaching $3.74. The stock had a trading volume of 130,579 shares, compared to its average volume of 2,908,461. Aquestive Therapeutics has a 1-year low of $2.93 and a 1-year high of $6.85. The company’s fifty day simple moving average is $4.60 and its two-hundred day simple moving average is $4.21. The company has a market cap of $468.91 million, a price-to-earnings ratio of -5.83 and a beta of 1.49.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Sherry Korczynski sold 8,750 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the sale, the insider directly owned 235,689 shares of the company’s stock, valued at $1,230,296.58. The trade was a 3.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $4.22, for a total value of $105,500.00. Following the transaction, the chief executive officer directly owned 627,317 shares of the company’s stock, valued at approximately $2,647,277.74. This represents a 3.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 58,750 shares of company stock valued at $271,675. Corporate insiders own 6.81% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AQST. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.60.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.